Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Strabismus, Delirium on Emergence, Pediatric Disorders
Interventions: Dexmedetomidine, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 1 Year to 7 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Alcoholism
Interventions: Ghrelin, Saline solution; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Shock, Hemorrhagic
Interventions: Plasma, Normal saline; Biological · Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Rotator Cuff Tears, Rotator Cuff Tendinitis, Rotator Cuff Impingement, Injections, Glucocorticoids
Interventions: FX006 Injection; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 40 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Sepsis, Severe Sepsis
Interventions: Intravenous fluid; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 5
States / cities: Newark, Delaware • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles
Interventions: KB304, 0.9% Normal Saline (NS); Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Hyperpolarized Helium-3, Placebo, Aformoterol; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 50 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Infertility of Uterine Origin
Interventions: AMD3100, Normal saline, dilation and curettage; Drug · Procedure
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Basking Ridge, New Jersey • Philadelphia, Pennsylvania

Conditions: Pain
Interventions: Normal saline as placebo comparator, Intravenous ibuprofen; Other · Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 6 more

Conditions: Congenital Heart Disease
Interventions: Antithrombin III, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 1 Day to 180 Days
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Torrance, California

Conditions: Cardiovascular Disease
Interventions: FEIBA, Normal Saline; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Urinary Tract Infection, Antibiotic, Catheter Infection
Interventions: 0.05% Chlorhexidine Gluconate, Normal Saline; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pulmonary Sarcoidosis
Interventions: PD 0360324, Normal Saline for injection; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 5
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Anorexia Nervosa, Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, Brain Injury
Interventions: Isoproterenol, Normal saline; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Lyme Disease
Interventions: VLA15, Normal Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 65
States / cities: Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more

Conditions: Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Tirofiban, Placebo; Drug
Lead sponsor: Dr David Hasan, M.D.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Carpal Tunnel Syndrome
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Benjamin Sucher; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,089 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 34
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more

Conditions: Post-operative Craniotomy Patients, Carotid Endarterectomy and Carotid Artery Stenosis Patients, Post-op Spine Patients Admitted to the NCCU, Endovascular Patients Undergoing Intracranial Intervention, Traumatic Brain Injuries NPO for at Least 12 Hours
Interventions: Intravenous acetaminophen, Placebo for IV acetaminophen; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 90 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

Effects of Ghrelin on Alcohol Cue Reactivity and Craving

Pre-Hospital Use of Plasma for Traumatic Hemorrhage

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

Preemptive Resuscitation for Eradication of Septic Shock

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

Endometrial Rejuvenation Study

Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

FEIBA and Use of Blood Products in Cardiac Surgery

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit